SCHEMBL23728848

SCHEMBL23728848

C[C@H](Nc1cc(Cl)ncc1[N+](=O)[O-])c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 1/20 0.57
CRHR2 Q13324 1/20 0.57
ALDH1A1 P00352 9/20 0.54
HTT P42858 3/20 0.54
GAA P10253 1/20 0.54
MAPT P10636 9/20 0.53
HTR6 P50406 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
HPGD P15428 1/20 0.50
KMT2A Q03164 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
RECQL P46063 1/20 0.47
POLB P06746 2/20 0.46
TP53 P04637 1/20 0.46
MAPK1 P28482 2/20 0.45
KDM4E B2RXH2 2/20 0.45
LMNA P02545 1/20 0.44
ASPH Q12797 1/20 0.44
RIOX2 Q8IUF8 1/20 0.44
KDM8 Q8N371 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25217426 1.00 CRHBP (0.57) CRHBPCRHR2ALDH1A1HTTGAA
SCHEMBL481941 0.85 CRHBP (0.57) CRHBPCRHR2ALDH1A1HTTGAA
SCHEMBL482005 0.85 CRHBP (0.57) CRHBPCRHR2ALDH1A1HTTGAA
SCHEMBL15740609 0.84 MERTK (0.43) CRHBPCRHR2ALDH1A1HTTGAA
SCHEMBL15740561 0.82 MAPT (0.46) CRHBPCRHR2ALDH1A1HTTGAA
SCHEMBL31531590 0.79 TSHR (0.42) CRHBPCRHR2ALDH1A1HTTMAPT
SCHEMBL31365054 0.79 TSHR (0.42) CRHBPCRHR2ALDH1A1HTTMAPT
SCHEMBL15742041 0.79 CYP3A4 (0.39) CRHBPCRHR2ALDH1A1HTTGAA
SCHEMBL15742042 0.79 CYP3A4 (0.39) CRHBPCRHR2ALDH1A1HTTGAA
SCHEMBL15740730 0.77 ALDH1A1 (0.50) ALDH1A1HTTGAAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240050576-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2024-02-15 US disclosed
US-20230149550-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2023-05-18 US disclosed
US-20230149550-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2023-05-18 US disclosed
CN-115768765-A Methods and compounds for treating genetic diseases 设计治疗公司 2023-03-07 CN disclosed
EP-4100404-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. (US) 2022-12-14 EP disclosed
WO-2021158707-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149550-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE DMPK, DTYMK, MYCBP CRHBP 290/4885CRHR2 2743/4885ALDH1A1 4368/4885
US-20240050576-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE ZFX, GRN, F13B CRHBP 358/4885CRHR2 2024/4885ALDH1A1 4800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.